投稿ビュー
Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update - Nasdaq
Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update Nasdaq Biotech company Ligand Pharmaceuticals Inc. ( LGND ) has agreed to buy genetic-engineering company OMT Inc. for about $ 178 million in cash and stock, a deal it says has potential for "significant" financial contribution and lengthy periods of patent ... |
投稿情報
18.12.2015 (3435日前)
評価
おすすめ
タグ
転職
"
"@type":
"@type":"NewsArticle"
"Auga Group"
"C" grade Nevada infrastructure
"Errol Oh"
"Jane Goodyear"
"Optimistically Cautious"
"a man and his prostate"
"akcijų pardavimas"
"analytics:simplereach:id":"54
"author":"Art Berman"
"author":"Brad McMillan"
"author":"Bryan Rich"
"author":"Christopher Helman"
"author":"Claire Poole"
"author":"Clare O'Connor"
"author":"David Blackmon"